Natera prenatal test gets extended insurance coverage

By staff writers

October 8, 2020 -- Healthcare insurer Centene has extended coverage of Natera's Panorama noninvasive prenatal test (NIPT) to all pregnant women.

The move comes on the heels of a joint guideline released by the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) that supports aneuploidy screening options, including NIPT, to all women, regardless of age or baseline pregnancy complication risk.

Panorama identifies a fetus's risk for severe genetic disorders as early as nine weeks into pregnancy using a single-nucleotide polymorphism-based technology to analyze fetal and placental DNA obtained through a blood draw from the mother, the company said.

Natera wins Medicare coverage for colorectal cancer test
Natera has received local coverage determination from the U.S. Centers for Medicare and Medicaid Services for serial use of the Signatera molecular residual...
Natera to collaborate with MGH on breast cancer trial
Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in...
Natera touts data supporting personalized ctDNA testing
Natera is highlighting clinical data that supports the efficacy of personalized circulating tumor DNA (ctDNA) testing for oligometastatic colorectal cancer.
Natera files patent lawsuit against Progenity
Natera has filed a lawsuit against Progenity for infringing six U.S. patents.
New technique improves Natera's organ transplant test
Natera has launched a new technique that enhances results from Prospera, the company's donor-derived cell-free DNA organ transplant laboratory-developed...

Copyright © 2020

Last Updated bc 10/9/2020 1:44:28 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.